BioSpace News Archive

MDxHealth SA, a commercial-stage precision diagnostics company, announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth.

Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, announced a groundbreaking study published in the Journal for ImmunoTherapy of Cancer.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

Iovance Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration has approved AMTAGVI™ suspension for intravenous infusion.

TransMedics Group, Inc. announced that on February 14, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 4,041 shares of its common stock and an aggregate of 2,627 restricted stock units to 9 employees, each as a material inducement for each employee’s entry into employment with TransMedics.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to four new employees.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced the closing of its previously announced public offering of 16,667,000 shares of common stock, at a public offering price of $0.30 per share.

Motus GI Holdings, Inc., announced that its special meeting of stockholders held on February 16, 2024 was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 24, 2024.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 131,688 shares of its common stock to four newly hired employees, consisting of inducement stock options to purchase an aggregate of 75,250 shares of common stock and inducement restricted stock units, covering an aggregate of 56,438 shares of its common stock.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced that it was notified by the World Trade Center Health Program that, due to a clerical error, the EsoGuard® Esophageal DNA test was incorrectly listed as a covered benefit.